收稿日期: 2019-07-30
网络出版日期: 2019-12-25
基金资助
国家自然科学基金(81460260);国家自然科学基金(81670121);国家自然科学基金(81770121)
吴凌云, 常春康 . 骨髓增生异常综合征的诊治最新进展[J]. 诊断学理论与实践, 2019 , 18(06) : 623 -629 . DOI: 10.16150/j.1671-2870.2019.06.004
| [1] | Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions[J]. Oncotarget, 2017, 8(43):73483-73500. |
| [2] | Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405. |
| [3] | Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med, 2014, 371(26):2488-2498. |
| [4] | Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis[J]. Nat Genet, 2012, 44(11):1179-1181. |
| [5] | Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J]. Blood, 2015, 126(1):9-16. |
| [6] | Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia[J]. Blood, 2017, 129(25):3371-3378. |
| [7] | Hansen JW, Westman MK, Sjö LD, et al. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes[J]. Am J Hematol, 2016, 91(12):1234-1238. |
| [8] | Balleari E, Clavio M, Arboscello E, et al. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes[J]. Leuk Res, 2011, 35(11):1472-1476. |
| [9] | 张宏丽, 秦铁军, 徐泽锋, 等. 重组人EPO治疗较低危骨髓增生异常综合征的临床疗效分析[J]. 中华血液学杂志, 2014, 35(1):18-23. |
| [10] | Garelius HK, Johnston WT, Smith AG, et al. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome[J]. J Intern Med, 2017, 281(3):284-299. |
| [11] | List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med, 2006, 355(14):1456-1465. |
| [12] | Santini V, Almeida A, Giagounidis A, et al. Randomized phase Ⅲ study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents[J]. J Clin Oncol, 2016, 34(25):2988-2996. |
| [13] | Cadenas-Cadenas FL, Lumbreras E, Xicoy B, et al.Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q)- Preliminary Blinded Analysis of the European Sintra-REV Trial[A].[60th American Society of Hematology Annual Meeting oral presentation]Blood 2018, 132(suppl 1):468. |
| [14] | Xiao L, Qi Z, Qiusheng C, et al. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression[J]. Am J Hematol, 2012, 87(1):26-31. |
| [15] | Stahl M, Bewersdorf JP, Giri S, et al. Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis[J]. Haematologica,2019,pii:haematol. 2019.219345. |
| [16] | Zeidan AM, Zhu W, Stahl M, et al. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis[J]. Leuk Lymphoma, 2019:1-7. |
| [17] | Baek DW, Lee YJ, Kim H, et al. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts[J]. Ann Hematol, 2018, 97(12):2309-2317. |
| [18] | Jabbour E, Short NJ, Montalban-Bravo G, et al. Rando-mized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J]. Blood, 2017, 130(13):1514-1522. |
| [19] | Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial[J]. Lancet Haematol, 2017, 4(3):e127-e136. |
| [20] | Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia[J]. Cancer, 2014, 120(12):1838-1846. |
| [21] | Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial[J]. Lancet Haematol, 2018, 5(3):e117-e126. |
| [22] | Santini V. Anemia as the main manifestation of myelodysplastic syndromes[J]. Semin Hematol, 2015, 52(4):348-356. |
| [23] | Angelucci E, Li J, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind telesto study[J]. Blood, 2018, 132:234. |
| [24] | Fenaux P, Platzbecker U, Mufti G J, et al. The medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell(RBC) transfusions[J]. Blood, 2018, 132:1. |
| [25] | Steensma DP, Platzbecker U, van Eygen K, et al. Imetelstat treatment leads to durable transfusion independence (TI) in RBC Transfusion Dependent (TD), Non-Del(5q) lower risk MDS relapsed/refractory to erythropoiesis-stimu-lating agent (ESA) who are lenalidomide (LEN) and HMA naïve[J]. Blood, 2018, 132:463. |
| [26] | Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase Ⅲ study[J]. Lancet Oncol. 2009 Mar; 10(3):223-232. |
| [27] | Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57. |
| [28] | Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial[J]. J Clin Oncol, 2009, 27(23):3842-3848. |
| [29] | Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada[J]. Br J Haematol, 2018, 181(6):803-815. |
| [30] | Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J]. N Engl J Med, 2016, 375(21):2023-2036. |
| [31] | Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes[J]. Br J Haematol, 2017, 176(4):600-608. |
| [32] | Xie M, Jiang Q, Li L, et al. HAG (homoharringtonine, cytarabine, G-CSF) regimen for the treatment of acute myeloid Leukemia and myelodysplastic syndrome: A meta-analysis with 2,314 participants[J]. PLoS One, 2016, 11(10):e0164238. |
| [33] | Wu L, Li X, Chang C, et al. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study[J]. Leuk Lymphoma, 2016, 57(6):1367-1374. |
| [34] | 中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志, 2019, 40(2):89-97. |
| [35] | Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial[J]. Lancet Haematol, 2019, 6(6):e317-e327. |
| [36] | Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethyla-ting drugs (ONTIME): a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(4):496-508. |
| [37] | Navada S, Garcia-Manero G, Atallah EL, et al. Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (Pts) with higher-risk (HR) myelodysplastic syndromes (MDS): Efficacy and safety results in HMA treatment naǐve & relapsed (Rel)/Refractory (Ref) Patients[J]. Blood, 2018, 132(suppl 1):230. |
| [38] | Taylor J, Coleman M, Alvarez J, et al. Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents[J]. Blood, 2018, 132(suppl 1):233. |
| [39] | Garcia-Manero G, Sasaki K, Montalban-Bravo G, et al. A phase Ⅱ study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)[J]. Blood, 2018, 132(suppl 1):465. |
| [40] | Gerds AT, Scott B, Greenberg PL, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: An initial safety and efficacy analysis[J]. Blood, 2018, 132(suppl 1):466. |
| [41] | Brierley CK, Steensma DP. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?[J]. Curr Opin Hematol, 2016, 23(2):167-174. |
| [42] | Yahng SA, Kim M, Kim TM, et al. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts[J]. Oncotarget, 2017, 8(7):12342-12354. |
/
| 〈 |
|
〉 |
